Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations
Blood Cancer Journal, Published online: 17 February 2023; doi:10.1038/s41408-023-00799-6Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - February 17, 2023 Category: Hematology Authors: Yuxuan Che Yang Liu Yixin Yao Holly A. Hill Yijing Li Qingsong Cai Fangfang Yan Preetesh Jain Wei Wang Lixin Rui Michael Wang Source Type: research
Artificial intelligence-enabled screening strategy for drug repurposing in monoclonal gammopathy of undetermined significance
Blood Cancer Journal, Published online: 17 February 2023; doi:10.1038/s41408-023-00798-7Artificial intelligence-enabled screening strategy for drug repurposing in monoclonal gammopathy of undetermined significance (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - February 17, 2023 Category: Hematology Authors: Alexander J. Ryu Shaji Kumar Angela Dispenzieri Robert A. Kyle S. Vincent Rajkumar Thomas C. Kingsley Source Type: research
CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases
Blood Cancer Journal, Published online: 17 February 2023; doi:10.1038/s41408-023-00800-2CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - February 17, 2023 Category: Hematology Authors: Rimal Ilyas Kristen McCullough Talha Badar Mrinal M. Patnaik Hassan Alkhateeb Abhishek Mangaonkar Animesh Pardanani Ayalew Tefferi Naseema Gangat Source Type: research
Circulating tumour DNA analysis predicts relapse and improves risk stratification in primary refractory multiple myeloma
Blood Cancer Journal, Published online: 13 February 2023; doi:10.1038/s41408-023-00796-9Circulating tumour DNA analysis predicts relapse and improves risk stratification in primary refractory multiple myeloma (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - February 13, 2023 Category: Hematology Authors: Sridurga Mithraprabhu John Reynolds Rose Turner Hang Quach Noemi Horvath Ian Kerridge Anna Kalff Krystal Bergin Jay Hocking Flora Yuen Tiffany Khong Brian M. Durie Andrew Spencer Source Type: research
Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma
Blood Cancer Journal, Published online: 07 February 2023; doi:10.1038/s41408-023-00793-yCorrection: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - February 7, 2023 Category: Hematology Authors: Keiji Kurata Anna James-Bott Mark A. Tye Leona Yamamoto Mehmet K. Samur Yu-Tzu Tai James Dunford Catrine Johansson Filiz Senbabaoglu Martin Philpott Charlotte Palmer Karthik Ramasamy Sarah Gooding Mihaela Smilova Giorgia Gaeta Manman Guo John C. Christian Source Type: research
Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeutics
Blood Cancer Journal, Published online: 03 February 2023; doi:10.1038/s41408-023-00791-0Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeutics (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - February 3, 2023 Category: Hematology Authors: Daisuke Ogiya Zuzana Chyra Sigitas J. Verselis Morgan O ’Keefe Jacquelyn Cobb Ivane Abiatari Srikanth Talluri Anjana Anilkumar Sithara Teru Hideshima Michael P. Chu Roman H ájek David M. Dorfman Linda M. Pilarski Kenneth C. Anderson Sophia Adamia Source Type: research
Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kδ inhibitors
Blood Cancer Journal, Published online: 02 February 2023; doi:10.1038/s41408-023-00788-9Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kδ inhibitors (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - February 2, 2023 Category: Hematology Authors: Deepti Gadi Stephen P. Martindale Pui Yan Chiu Jasneet Khalsa Pei-Hsuan Chen Stacey M. Fernandes Zixu Wang Svitlana Tyekucheva John-Hanson Machado David C. Fisher Philippe Armand Matthew S. Davids Scott Rodig Barbara Sherry Jennifer R. Brown Source Type: research
Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis
Blood Cancer Journal, Published online: 30 January 2023; doi:10.1038/s41408-023-00786-xPhenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 30, 2023 Category: Hematology Authors: Paola Guglielmelli Chiara Maccari Benedetta Sordi Manjola Balliu Alessandro Atanasio Carmela Mannarelli Giulio Capecchi Ilaria Sestini Giacomo Coltro Giuseppe Gaetano Loscocco Giada Rotunno Eva Angori Filippo C. Borri Ayalew Tefferi Alessandro M. Vannucch Source Type: research
DNA-PK hyperactivation occurs in deletion 11q chronic lymphocytic leukemia and is both a biomarker and therapeutic target for drug-resistant disease
Blood Cancer Journal, Published online: 27 January 2023; doi:10.1038/s41408-022-00781-8DNA-PK hyperactivation occurs in deletion 11q chronic lymphocytic leukemia and is both a biomarker and therapeutic target for drug-resistant disease (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 27, 2023 Category: Hematology Authors: Sara E. F. Kost Ali Saleh Shek H. Yuan Bozena Kuzio Spencer B. Gibson Lin Yang Versha Banerji James B. Johnston Sachin Katyal Source Type: research
The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018
Blood Cancer Journal, Published online: 25 January 2023; doi:10.1038/s41408-023-00789-8The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018 (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 25, 2023 Category: Hematology Authors: Giovanni Palladini Stefan Sch önland Giampaolo Merlini Paolo Milani Arnaud Jaccard Frank Bridoux Meletios A. Dimopoulos Sriram Ravichandran Ute Hegenbart Wilfried Roeloffzen M. Teresa Cibeira Hermine Agis Monique C. Minnema Rui Bergantim Roman H ájek Cr Source Type: research
Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome
Blood Cancer Journal, Published online: 24 January 2023; doi:10.1038/s41408-023-00790-1Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 24, 2023 Category: Hematology Authors: Jan-Niklas Eckardt Sebastian Stasik Christoph R öllig Tim Sauer Sebastian Scholl Andreas Hochhaus Martina Crysandt Tim H. Br ümmendorf Ralph Naumann Bj örn Steffen Volker Kunzmann Hermann Einsele Markus Schaich Andreas Burchert Andreas Neubauer Kerstin Source Type: research
Humoral and cellular responses after COVID-19 booster vaccination in patients recently treated with anti-CD20 antibodies
Blood Cancer Journal, Published online: 23 January 2023; doi:10.1038/s41408-023-00792-zHumoral and cellular responses after COVID-19 booster vaccination in patients recently treated with anti-CD20 antibodies (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 23, 2023 Category: Hematology Authors: Masashi Nishikubo Yoshimitsu Shimomura Ryusuke Yamamoto Satoshi Yoshioka Hayato Maruoka Seiko Nasu Tomomi Nishioka Kenji Sakizono Satoshi Mitsuyuki Tomoyo Kubo Naoki Okada Daishi Nakagawa Kimimori Kamijo Hiroharu Imoto Yuya Nagai Nobuhiro Hiramoto Noboru Source Type: research
Alternative splicing in multiple myeloma is associated with the non-homologous end joining pathway
Blood Cancer Journal, Published online: 20 January 2023; doi:10.1038/s41408-023-00783-0Alternative splicing in multiple myeloma is associated with the non-homologous end joining pathway (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 20, 2023 Category: Hematology Authors: Enze Liu Nathan Becker Parvathi Sudha Chuanpeng Dong Yunlong Liu Jonathan Keats Gareth Morgan Brian A. Walker Source Type: research
Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019
Blood Cancer Journal, Published online: 13 January 2023; doi:10.1038/s41408-023-00784-zRisk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019 (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 13, 2023 Category: Hematology Authors: Lina van der Straten Mark-David Levin Manette A. W. Dinnessen Otto Visser Eduardus F. M. Posthuma Jeanette K. Doorduijn Anton W. Langerak Arnon P. Kater Avinash G. Dinmohamed Source Type: research
A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma
Blood Cancer Journal, Published online: 12 January 2023; doi:10.1038/s41408-022-00768-5A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 12, 2023 Category: Hematology Authors: Wee-Joo Chng Sagar Lonial Gareth J. Morgan Shinsuke Iida Philippe Moreau Shaji K. Kumar Philip Twumasi-Ankrah Miguel Villarreal Ajeeta B. Dash Alexander Vorog Xiaoquan Zhang Kaveri Suryanarayan Richard Labotka Meletios A. Dimopoulos S. Vincent Rajkumar Source Type: research
